Journal of International Oncology››2019,Vol. 46››Issue (9): 562-565.doi:10.3760/cma.j.issn.1673-422X.2019.09.011

Previous ArticlesNext Articles

Transforming growth factor-β signaling pathway and targeted therapy in ovarian cancer

Tang Nanmin1, Yu Zhancai2

  1. 1Department of Gynaecology and Obstetrics, People′s Hospital of Longchang City, Sichuan Province, Longchang 642150, China;2Department of Oncology, Weihai Municipal Hospital, Shandong Province, Weihai 264200, China
  • Received:2019-07-11Online:2019-09-08Published:2019-09-08
  • Contact:Yu Zhancai E-mail:lzg6598@126.com

Abstract:The transforming growth factor-β (TGF-β) is a polypeptide cytokine, belonging to the TGF-β superfamily. TGF-β signaling pathway can regulate cell biological activity and play a bidirectional regulatory role in the development and progression of cancer. TGF-β signaling pathway can cause the occurrence and development of ovarian cancer through various processes including inducing cell excessive proliferation, influencing tumor microenvironment and regulating immune evasion. Targeted therapy with TGFβ as a biomarker for ovarian cancer provides a new way to improve the prognosis of patients.

Key words:Ovarian neoplasms,Transforming growth factor β,Molecular targeted therapy